Drug
BI 655064 clinical trials
Also written BI 655064.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
- BI 655064
- 6
Studies by the year they started
7 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses BI 655064 is read from its arms, and is right about nine times in ten.
Testing it · 7
- Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus NephritisCompletedPhase 2Boehringer IngelheimNCT02770170Written as BI 655064 dose 1
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate TherapyCompletedPhase 1Boehringer IngelheimNCT01751776Written as BI 655064
- Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).TerminatedPhase 1Boehringer IngelheimNCT02009761Written as BI 655064
- Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02331277Written as BI 655064
- Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male VolunteersCompletedPhase 1Boehringer IngelheimNCT01917916Written as BI 655064
- An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus NephritisCompletedPhase 2Boehringer IngelheimNCT03385564Written as BI 655064
- Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT01510782Written as BI 655064